Investing.com — Evolus, Inc. (NASDAQ: NASDAQ:EOLS) stock rose 17% following the company’s announcement of preliminary unaudited fourth quarter and full-year 2024 net revenue, along with its guidance for 2025 that surpassed market expectations.
The aesthetic portfolio company reported a 30% increase in fourth quarter net revenues compared to the same period last year, reaching $79.0 million, which exceeded the consensus forecast of $77 million. Full-year net revenues for 2024 climbed to $266.3 million, marking a 32% growth over the previous year and hitting the upper end of the company’s guidance range.
Evolus attributed the robust performance to significant market share gains, particularly with its flagship neurotoxin product, Jeuveau®, in the U.S. market, and the international expansion of Nuceiva®. The company’s CEO, David Moatazedi, highlighted consistent revenue growth over the past five years, attributing it to the company’s effective business model and performance beauty approach.
The company also provided an optimistic outlook for 2025, estimating total net revenues to be between $345 million and $355 million, which would represent a 30% to 33% increase from 2024’s preliminary results. This guidance is above the consensus estimate of $352 million for FY25. The anticipated growth is partly due to the expected contributions from the upcoming launch of Evolysse and Estyme® injectable HA gels, which are projected to account for 8-10% of total revenue for the year.
Moreover, Evolus expects to achieve positive non-GAAP operating income for the full year of 2025, with significant growth projected for the fourth quarter following the launch of their new products. The company also reported an increase in cash and cash equivalents, highlighting strong sales growth, cash collections, and prudent expense management.
The market’s positive reaction to Evolus’ earnings and guidance reflects investor confidence in the company’s growth trajectory and its ability to capitalize on its expanding product portfolio. With the FDA approval for Evolysse injectable HA gels expected within the next 90 days and a U.S. launch planned for the second quarter of 2025, Evolus is poised to transition from a single product company to a multi-product innovator in the performance beauty space.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
